Fleury (FLRY3.SA) Stock Price

Fleury Price

B3·CLOSED
20.47
​
Market closed

Over the last 19 years Fleury grew revenue by 16.1% annually, reaching 8.29 B BRL. Earnings per share have grown at 12.5% per year over the last 19 years. For Fleury, the net margin of 7.4% is down versus 9.0% a few years ago. At today's price the dividend yield works out to roughly 8.18%. The payout ratio is around 149% of earnings. The dividend has grown at 20.5% per year over the past 15 years. The consensus 12-month price target for Fleury is 18.36 BRL, about 10.3% below where the stock trades today. Of 19 analysts, 11 rate the stock a buy — an overall Buy consensus.

Fleury stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Fleury business model & stock analysis

The history of Fleury SA begins in 1926 when the Fleury family opened a small butcher shop in Lyon, France. The family quickly gained a reputation for their high-quality meats and sausages and started supplying restaurants and hotels. Over the following decades, Fleury SA developed into a leading company in the food industry. The management recognized the importance of innovation and diversification early on, and the company became a major provider of frozen and fresh products, including meat, fish, and vegetables. Today, Fleury SA is an internationally operating company based in Lyon with branches in several countries. The company's core business includes the production and marketing of food in four different areas: 1) Fresh products: Fleury SA is known for its high-quality meats and sausages, including beef, pork, poultry, and game. The company also offers a wide range of fish products, including salmon, trout, and tuna. 2) Frozen products: Fleury SA is a significant supplier of frozen products, including meat, fish, vegetables, and ready meals. The company places great importance on the high quality and sustainability of its products. 3) Food ingredients: Fleury SA also produces a range of food ingredients that are widely used in the food industry. These include spices, herbs, and flavors. 4) Private labels: Another important division of Fleury SA is the production of private labels. The company works with retailers to manufacture their products under their own brand. Fleury SA's products are sold through a variety of distribution channels, including supermarkets, restaurants, and hotels. The company also heavily relies on its online presence and offers a wide range of products through its online shop. Over the years, the company has received numerous awards for its products and innovations. Fleury SA is proud of its efforts to promote sustainable and ethical business practices and is committed to environmental protection and animal welfare in the food industry. Overall, Fleury SA is a successful and innovative company that stays true to its roots and values. Through its focus on quality, sustainability, and diversification, the company has secured a solid position in the food industry.

Frequently asked questions about Fleury

The business model of Fleury SA, a leading medical diagnostics company in Brazil, revolves around providing high-quality healthcare services through its network of diagnostic imaging, clinical analysis, and other medical services. Fleury SA aims to ensure accurate diagnoses, offer timely access to medical procedures, and deliver exceptional customer experience. By investing in advanced technology, top-notch professionals, and continuous innovation, Fleury SA effectively meets the healthcare needs of patients across the country. With its strong reputation and diverse range of diagnostic services, Fleury SA strives to maintain its position as a market leader in Brazil's healthcare industry.

Fleury SA is primarily active in the healthcare industry.

The main competitors of Fleury SA in the market include Grupo Fleury, DASA, and Hermes Pardini.

Fleury SA is a leading healthcare company based in Brazil. With a rich history dating back to 1926, Fleury has continually evolved and expanded its operations to become one of the most reputable diagnostic medicine providers in the country. Over the years, the company has developed a strong reputation for its advanced diagnostic techniques and high-quality services, encompassing radiology, pathology, and clinical analysis. With a strong focus on technological innovation, Fleury has consistently invested in cutting-edge equipment and research, enabling them to deliver accurate and reliable results to patients. Today, Fleury SA stands as a trusted name in the healthcare industry, providing comprehensive diagnostic solutions to improve patient outcomes.

Fleury SA, a renowned company, has achieved remarkable milestones throughout its history. Having established a strong presence in the healthcare sector, Fleury SA continuously strives for excellence. Some significant achievements include expanding its network and becoming one of the largest healthcare providers in Brazil. Additionally, Fleury SA has consistently prioritized innovation, implementing advanced technology and processes to deliver high-quality diagnostics and medical solutions. The company's commitment to patient-centric care and a strong focus on research & development have further solidified its position as a trusted leader in the industry. Fleury SA's relentless pursuit of growth and unwavering dedication to improving healthcare services have contributed to its notable achievements.

Fleury SA is primarily present in Brazil, where it operates a wide network of diagnostic medicine and healthcare facilities. With its headquarters in São Paulo, the company is a leader in medical laboratory services, operating in several states across the country. Fleury SA's commitment to providing high-quality diagnostic services has allowed it to expand its presence to other regions of Brazil, catering to a diverse range of patients and medical professionals.

Fleury SA represents a strong set of values and corporate philosophy. With a focus on excellence and innovation, the company strives to deliver the highest quality healthcare services to patients. Fleury SA is committed to providing accurate diagnoses, personalized care, and cutting-edge medical technology. Through continuous improvement, the company aims to surpass industry standards and meet the evolving needs of its customers. With a reputation for professionalism and integrity, Fleury SA upholds a patient-centric approach, putting the well-being and satisfaction of individuals at the forefront. By encompassing these values, Fleury SA remains a trusted leader in the healthcare industry.

Analysts currently set an average price target of 17.77 BRL for the Fleury stock (median: 18.36 BRL), implying -13.2 % versus the latest price. The consensus is based on 19 analyst ratings.

18 analysts currently rate the Fleury stock: 11 recommend buying, 5 holding and 2 selling. For 2026, analysts expect Fleury to generate revenue of 9.28 B BRL and earnings per share of 1.47 BRL.

Converted at the current exchange rate, the Fleury share trades at 3.34 EUR (20.47 BRL).

The Fleury share (FLRY3.SA) is listed on 2 stock exchanges, including: B3 (São Paulo) (FLRY3.SA).

Fleury SA is a company specializing in medical diagnostics and health services. Founded in 1926, the company is headquartered in Sao Paulo, Brazil. With over 9,000 employees and a revenue of more than 2.2 billion Brazilian Reals, Fleury SA is one of the largest medical service companies in South America. The business model of Fleury SA is based on three core areas: diagnostics, health services, and research and development. In diagnostics, the company enables disease identification and offers comprehensive diagnostic solutions. The portfolio of diagnostic services is very broad and includes imaging and radiological diagnostics, laboratory and pathology services, genetic testing, and screening for pregnancy-related diseases. In the field of health services, Fleury SA offers a wide range of services for individuals and companies looking to improve prevention, wellness, and quality of life. The services range from health counseling and health programs to outpatient surgery and rehabilitation facilities. In research and development, the company is interested in driving innovation in the fields of medical diagnostics and health services. Fleury SA invests heavily in the development of new technologies and solutions to improve the accuracy and efficiency of its diagnostic services, as well as in collaboration with academic institutions and other companies. The company is known for adhering to very high quality standards in all aspects of its services. Fleury SA is ISO 9001 certified and is committed to continuously working towards customer satisfaction and process optimization. The company is proud to offer state-of-the-art technology and top-notch medical professionals to provide customers with the best possible service. In addition to its business areas, Fleury SA also offers a variety of products, such as diagnostic instruments and consumables for medical professionals, medical software, and health products for the general public. The products are designed to meet the needs of medical professionals and private consumers and meet the highest quality standards. Overall, Fleury SA has an impressive track record in the field of medical diagnostics and health services. The company has established itself as a trusted provider of high-quality and innovative solutions over the past decades and is committed to continuing to lead the industry with excellence and groundbreaking innovations.

The expected revenue of Fleury is 9.28 B BRL. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Fleury is 802.36 M BRL. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Fleury is currently 13.91. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Fleury stock.

The price-to-sales ratio (P/S) of Fleury is currently 1.20. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Fleury stock.

The Eulerpool Quality Score for Fleury is 8/10.

The ISIN of Fleury is BRFLRYACNOR5. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Fleury is FLRY3.SA. The ticker symbol is used to trade Fleury shares on the stock exchange.

Fair ValueTerminal
16.79 BRL
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Health Care Providers & Services
Number of shares
Employees
Revenue per Employee
496,477.96 BRL
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Brazil
Currency
BRL
Initial public offering
Dec 16, 2009
ISIN
BRFLRYACNOR5
Cusip
P418BW104
Sedol
B4X4D29
Market capitalization
11.16 B BRLLarge Cap
52-Week Range
PEG
1.74
P/E ratio
P/Ee 2026
13.90
P/Ee 2027
12.04
P/Ee 2028
10.49
P/Ee 2029
9.99
P/Ee 2030
8.46
P/S
P/Se
1.20
EV/EBIT
12.65
P/B Ratio
2.23
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
6.55 %
Dividend
Dividend yield
8.18 %
Est. Dividend Yield
3.92 %
Payout Ratio
149.00 %
Dividend growth Ø5Y
—
Dividend payments per year
3
Dividend paid since
16 years
Dividend not reduced since
2 years
Dividend increased since
2 years
Dividend withholding tax
10.00 %
Last updated Nov 4, 2026, 10:08 AM

Fleury Peer Group

Fleury Ticker

B3 · FLRY3.SAB3 · FLRY3.SA

Fleury FIGI

FLRY3:BZ · BBG000PRQZM2FLRY3:BS · BBG000PRR0C9FLRY3:BN · BBG000PRR1F4FLRYF:PQ · BBG004V9MJ74FLRYF:UV · BBG004V9MJ92

All fundamentals and in-depth analysis of Fleury

Our stock analysis for Fleury stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Fleury. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.